etaracizumab

Etaracizumab is a humanized IgG1 monoclonal antibody that targets the **alpha-v beta-3 (αvβ3) integrin**, a cell surface protein highly expressed on newly forming blood vessels (angiogenesis), certain tumor cells (such as melanoma), and osteoclasts. Developed by MedImmune, the drug was designed to inhibit tumor growth, angiogenesis, and bone metastases by blocking the interaction of the αvβ3 integrin with its extracellular matrix ligands, such as vitronectin and osteopontin. Its mechanism of action also includes the induction of antibody-dependent cellular cytotoxicity (ADCC) against cells expressing the target. While etaracizumab showed promise in preclinical models and early-phase trials for metastatic melanoma and androgen-independent prostate cancer, a randomized Phase 2 study in melanoma patients demonstrated that it did not provide a clinically meaningful survival benefit over standard dacarbazine treatment. Consequently, its clinical development for oncology and inflammatory indications, including rheumatoid arthritis and psoriasis, was discontinued.

Brand names

AbegrinVitaxin

Other names

etaracizumabMEDI522MEDI-522MEDI 522anti-alphaVbeta3 antibodyanti-alphaVbeta-3 antibodyanti-alphaVbeta 3 antibody